magnet
reson
imag
find
plasma
exosom
deriv
prostat
acinar
cell
investig
new
biomark
diagnosi
prostat
cancer
see
proteom
profil
exosom
show
potenti
biomark
diseas
see
patient
experienc
recurr
hepatocellular
carcinoma
liver
transplant
show
increas
level
mirna
biomark
serum
exosom
see
exosom
also
evalu
biomark
variou
noncanc
diseas
multipl
organ
includ
central
nervou
system
cn
see
liver
see
kidney
see
lung
see
arteri
see
cn
taumedi
neuropatholog
result
extracellular
accumul
abnorm
process
tau
protein
see
cell
neuroblastoma
tauopathi
model
tau
protein
appear
spread
via
exosom
phosphorylatedtau
increas
cerebrospin
fluid
csf
biomark
earli
stage
alzheim
diseas
ad
elev
level
tau
csf
seen
mild
moder
case
sporad
ad
result
select
abund
phosphoryl
tau
exosom
portion
csf
rel
total
csf
tau
increas
csf
phosphoryl
tau
level
attack
ad
associ
increas
exosomeassoci
portion
csf
anoth
studi
level
autolysosom
protein
cathepsin
lysosomalassoci
membran
protein
ubiquitinyl
protein
neuronderiv
serum
exosom
distinguish
patient
preclin
ad
match
control
patient
frontotempor
dementia
see
alter
microrna
profil
csfblood
exosom
associ
neurodegen
disord
possibl
new
biomark
earli
diagnosi
ad
pd
see
fact
exosom
deliv
sirna
offer
therapeut
potenti
ad
see
proteom
profil
serum
exosom
identifi
protein
abund
patient
pd
compar
healthi
subject
see
regard
lung
diseas
exosom
isol
bronchoalveolar
lavag
fluid
patient
asthma
compar
healthi
subject
show
differ
mirna
profil
see
exosom
releas
key
cell
implic
asthma
mast
cell
eosinophil
dendrit
cell
dc
tcell
bronchial
epitheli
cell
turn
provok
activ
repress
asthmarel
cell
stimul
allerg
respons
see
dcderiv
exosom
dex
dexosom
costimulatori
molecul
surfac
stimul
allergenspecif
cell
see
eosinophilderiv
exosom
also
import
role
modul
asthma
number
increas
asthmat
patient
see
exosom
mirna
content
patient
sever
asthma
significantli
differ
compar
healthi
subject
see
dysregul
mirna
associ
pathway
relat
airway
integr
well
correl
certain
clinic
featur
eosinophil
count
see
differ
studi
exosom
mirna
profil
patient
sever
asthma
relat
erbb
signal
pathway
focal
adhes
see
exosom
may
also
serv
vaccin
allerg
diseas
see
exosom
isol
bronchoalveolar
lavag
fluid
mice
respiratori
exposur
oliv
pollen
allergen
induc
toler
protect
allerg
sensit
mice
see
increas
level
serum
exosom
predict
develop
heart
failur
acut
myocardi
infarct
see
final
urinari
exosom
use
start
materi
diagnost
biomark
renal
urogenit
system
diseas
see
despit
number
studi
show
relev
ev
biomark
divers
diseas
result
individu
studi
shown
inconsist
trend
methodolog
differ
ev
purif
may
explain
contradict
see
given
applic
mandatori
inspect
method
term
sensit
specif
includ
qualiti
control
measur
welldefin
set
exosom
preferenti
candid
use
vaccin
infecti
diseas
toxoplasmosi
diphtheria
tuberculosi
atyp
sever
acut
respiratori
syndrom
sar
report
immun
use
dc
toxoplasma
gondii
antigen
tag
healthi
mice
induc
protect
virul
strain
gondii
oral
applic
difficult
obtain
suffici
amount
dc
pertin
vaccin
see
murin
bone
marrowderiv
dc
puls
vitro
intact
diphtheria
toxin
dt
releas
exosom
inject
mice
show
induct
respons
specif
dt
see
infect
mycobacterium
tuberculosi
excit
macrophag
stimul
releas
exosom
note
exosom
contain
tuberculosi
peptidemhcii
complex
induc
antimicrobi
tcell
respons
see
exosom
vaccin
materi
also
studi
sarsrel
coronaviru
cov
infect
caus
fatal
atyp
pulmonari
diseas
kuat
et
al
found
exosom
sarscov
spike
protein
produc
neutral
antibodi
titer
reinforc
prime
sarss
exosom
vaccin
boost
present
appli
adenovir
vector
vaccin
see
stimul
potent
gener
cytotox
lymphocyt
ctl
immun
reaction
therapeut
potenti
variou
diseas
includ
viral
infect
exampl
induc
antiebola
viru
ebov
specif
ctl
immun
could
benefit
therapeut
prevent
set
see
fact
stimul
virusspecif
ctl
recogn
survivor
acut
ebov
infect
see
virusspecif
ctl
immun
play
crucial
role
protect
sever
nonhuman
primat
includ
macaqu
see
furthermor
transfus
lymphocyt
mice
infect
mouseadapt
ebov
recipi
mice
defend
ebov
infect
see
consist
power
ctlrelat
immun
respons
could
also
pertin
therapeut
effect
influenza
virus
flu
see
hepat
c
hcv
viru
infect
see
anticoli
et
al
suggest
exosomebas
vaccin
platform
design
exosom
vivo
protein
human
papilloma
viru
hpv
method
involv
intramuscular
inject
dna
vector
encod
fuse
cterminu
exosomeanchor
nef
mutant
protein
nef
mut
human
immunodefici
viru
nef
mut
protein
see
connect
raft
microdomain
cellular
membran
see
nef
mut
lack
sever
anticellular
effect
gener
caus
wildtyp
nef
includ
downregul
increas
infect
stimul
mhc
class
downregul
found
exosom
high
level
see
align
protein
produc
potent
effect
antigenspecif
ctl
immun
establish
gener
applic
technolog
immunogen
studi
perform
array
viral
product
variou
origin
size
includ
ebov
west
nile
viru
hcv
antigen
stabl
upon
fusion
nef
mut
transfer
exosom
level
compar
nef
mut
inject
mice
dna
vector
express
variou
fusion
product
produc
clearli
detect
antigenspecif
cell
respons
suffici
cytotox
kill
peptideload
andor
antigenexpress
syngen
cell
see
dc
compet
cell
present
antigen
antigenpres
cell
abl
stimul
cell
creat
adapt
immun
reaction
see
inde
defin
cancer
immunosurveil
stage
stepwis
result
lead
effect
kill
cancer
cell
cell
specif
dc
captur
process
tumor
neoantigen
first
phase
process
depend
molecular
signal
proinflammatori
cytokin
costimulatori
ligand
die
tumor
cellsderiv
molecul
gut
microbiom
product
see
accordingli
potent
dcbase
cancer
vaccin
research
time
posit
result
use
technolog
emerg
sipuleucelt
immunotherapi
castrationresist
prostat
cancer
see
howev
divers
applic
dcbase
cancer
vaccin
show
main
limit
see
fig
describ
dcbase
immunotherapeut
strategi
dexosom
dex
base
cancer
vaccin
recent
emerg
altern
may
overcom
obstacl
first
dex
molecular
compon
simpl
analyz
thu
enabl
rigid
definit
valid
paramet
see
second
dex
compon
plenti
peptidemhc
class
ii
complex
allow
higher
yield
see
third
dex
compar
dc
toler
longerterm
frozen
storag
month
see
addit
merit
immunosuppress
tumor
microenviron
often
inhibit
antigen
present
cell
stimul
dc
affect
dex
see
final
dex
associ
risk
relat
administr
viabl
cell
gener
immun
dysfunct
microvascular
occlus
see
tumor
peptidepuls
dex
produc
vivo
ctl
prime
tumor
growth
repress
tumor
remiss
inde
singl
intraderm
inject
stimul
signific
tumor
growth
repress
week
anim
tumorfre
day
see
furthermor
dcsbase
immunotherapeut
strategi
harvest
peripher
blood
mononuclear
cell
gener
immatur
dc
cytokin
stimul
matur
dc
sens
presenc
potenti
pathogen
stress
signal
via
detect
pamp
exogen
signal
infectioninduc
alter
selfmark
endogen
signal
cancer
cell
brought
contact
dendrit
cell
consum
therebi
imprint
dendrit
cell
cancer
marker
transfer
activ
antigenpres
dc
back
patient
stimul
robust
antitumor
immun
effector
cell
cell
nk
cell
cellfre
immunotherapeut
vaccin
potent
directli
administ
viabl
dc
vaccin
mice
tumorfre
day
differ
may
illustr
exosom
resist
immunomodulatori
effect
tumor
microenviron
block
abil
dc
present
antigen
see
past
decad
sever
success
clinic
trial
perform
assess
feasibl
safeti
efficaci
dexbas
cancer
vaccin
patient
nonsmal
cell
lung
cancer
nsclc
see
metastat
melanoma
see
gener
result
promis
trial
patient
receiv
four
dose
vaccin
consist
autolog
dex
load
sever
differ
mhc
class
ii
peptid
vaccin
product
shown
practic
therapi
well
toler
minor
grade
advers
event
see
recent
phase
ii
clinic
trial
evalu
use
dex
deriv
matur
dc
mainten
immunotherapi
use
firstlin
chemotherapi
patient
advanc
nsclc
see
studi
show
feasibl
product
safeti
one
patient
develop
grade
hepatotox
trial
show
object
tumor
respons
among
clinic
outcom
accord
respons
evalu
criteria
solid
tumor
howev
show
patient
longest
progressionfre
surviv
notabl
improv
nk
cell
function
dex
treatment
show
dex
stimul
nk
cell
arm
antitumor
immun
patient
advanc
nsclc
see
tumorderiv
exosom
also
function
antigen
deliveri
system
capabl
block
tumor
develop
celldepend
pattern
see
cellfre
vaccin
base
use
tumorderiv
exosom
anoth
possibl
clinic
applic
howev
isol
tumorderiv
exosom
inconveni
low
prepar
effici
low
yield
vitro
cultur
patient
tumor
cell
see
howev
malign
effus
patient
melanoma
rich
exosom
transmit
tumor
antigen
dc
turn
stimul
tumorspecif
ctl
capabl
effect
vitro
antitumor
respons
see
phase
clinic
trial
examin
effect
exosom
harvest
ascit
patient
advanc
crc
immunotherapi
show
combin
tumor
exosom
gmcsf
permit
effect
induct
system
antitumor
immun
ctl
respons
compar
tumor
exosom
alon
patient
treat
tumor
exosom
show
therapeut
respons
one
patient
stabl
diseas
one
patient
minor
clinic
respons
observ
group
treat
ascitesderiv
exosom
combin
gmcsf
see
despit
attempt
engag
thu
far
dexbas
immunotherapi
novel
cancer
control
remain
highli
encourag
possibl
dex
profici
mediat
immun
respons
technic
simplic
manag
immunostimulatori
characterist
via
donor
dc
along
advantag
whole
cellbas
applic
confirm
therapeut
promis
see
particular
interest
section
exosom
serv
promot
tumor
growth
invas
establish
immunosuppress
microenviron
agent
cancer
immunosurveil
induc
antigen
present
stimul
destruct
tumor
cell
see
see
cell
compon
innat
immun
system
nk
cell
see
fig
import
characterist
success
nanocarri
satisfactori
vivo
behavior
develop
ev
deliveri
system
requir
comprehens
vivo
kinet
administr
howev
understand
extracellular
behavior
pathway
cell
uptak
subcellular
path
ev
remain
obscur
ev
releas
variou
type
cell
found
rel
stabl
blood
circul
biolog
fluid
suggest
ev
slowli
clear
remain
longer
synthet
nanocarri
biolog
system
howev
differ
vivo
pharmacokinet
studi
shown
ev
inject
circul
rapidli
clear
ev
deriv
melanoma
cell
splenocyt
underw
rapid
clearanc
show
short
halflif
approxim
min
intraven
administr
mice
see
increas
level
fetuina
urinari
exosom
correl
acut
urinari
injuri
see
exosom
microvesicl
particip
larg
varieti
bodi
process
carrier
concentr
genet
proteom
inform
thu
believ
play
import
role
celltocel
commun
secret
vesicl
carri
messag
differ
way
firstli
may
stimul
recipi
target
cell
via
ligand
express
surfac
exampl
verifi
antigenpres
exosom
deriv
dc
induc
cellmedi
immun
respons
vivo
see
addit
ligandreceptor
signal
via
exosom
also
play
role
regulatori
process
angiogenesi
see
hemostasi
see
cancer
progress
see
metastasi
see
secondli
secret
ev
may
transfer
surfac
receptor
one
cell
anoth
fusion
plasma
membran
target
cell
see
mechan
hiv
increas
suscept
infect
transfer
receptor
infect
cell
intact
cell
see
ev
appear
multipl
obviou
advantag
high
deliveri
capac
innat
target
properti
low
immunogen
potenti
posit
effici
biolog
deliveri
system
therapeut
rang
small
molecul
macromolecular
nucleic
acid
protein
see
tabl
despit
develop
variou
methodolog
evbas
deliveri
major
hurdl
lack
standard
effici
reason
approach
isol
ev
isol
method
need
valid
consid
reproduc
yield
puriti
function
properti
ev
gener
applic
also
valid
standard
procedur
storag
time
need
care
evalu
evbas
product
see
fig
show
overal
scheme
differ
modal
use
exosomebas
formul
see
also
load
effici
therapeut
ev
remain
inadequ
rel
tight
order
lipid
bilay
imped
effici
load
drug
ev
without
reduc
membran
integr
damag
might
alter
immuneori
characterist
ev
make
visibl
mononuclear
phagocyt
system
see
therefor
ideal
load
method
possess
high
load
effici
also
preserv
structur
integr
ev
function
integr
therapeut
see
grow
area
interest
applic
divers
nanotechnologybas
dd
liposom
polymer
nanoparticl
dendrim
magnet
nanoparticl
see
deliveri
system
use
deliv
variou
type
cargo
includ
chemotherapeut
antiinflammatori
drug
mirna
see
nanos
diamet
dd
facilit
deliveri
blood
lymphat
system
effect
drugload
capac
see
moreov
understand
progress
regard
nanoscal
vesicl
biocompat
stabil
bodi
fluid
natur
deriv
low
immunogen
stealth
capac
immun
system
inher
target
properti
reduc
offtarget
effect
abil
guid
therapeut
cargo
across
biolog
barrier
especi
bbb
capac
load
specif
small
molecul
mirna
drug
uniqu
composit
allow
direct
membran
fusion
target
cell
effici
cell
uptak
safe
clinic
trial
low
inher
toxic
secret
uptak
mechan
composit
biolog
function
yet
understood
impact
target
cell
unknown
isol
techniqu
high
effici
robust
yield
lack
scalabl
product
difficultther
optim
purif
method
largescal
product
expens
challeng
effici
load
method
without
damag
ev
integr
lack
vivo
data
less
studi
vivo
track
requir
studi
clinic
studi
therapeut
deliveri
lack
vesicl
heterogen
constitu
immunogen
vivo
pharmacokinet
behavior
ev
circulatori
halflif
tissu
distribut
vivo
cellular
uptak
intracellular
fate
understand
crucial
clarif
biolog
function
exosom
practic
applic
exosomebas
therapeut
defin
pharmacokinet
exosom
clearli
first
step
includ
evalu
tissu
distribut
vivo
word
socal
biodistribut
exosom
sever
label
method
small
lipophil
fluoresc
dye
introduc
use
purpos
vivo
track
although
reliabl
vivo
analysi
would
decreas
releas
free
dye
exosom
strategi
use
approach
assess
local
exosom
tissu
see
lipophil
fluoresc
dye
use
label
highli
metastat
murin
melanoma
cellderiv
exosom
accumul
lung
bone
marrow
spleen
liver
enhanc
endotheli
permeabl
lung
facilit
tumor
metastasi
lung
see
addit
fluoresc
dye
lipophil
nearinfrar
dye
perchlor
iodid
dir
wide
use
imag
exogen
administ
exosom
didlabel
msc
exosom
well
distribut
spleen
liver
intraven
administr
normal
mice
see
hand
mous
model
acut
kidney
injuri
exosom
accumul
kidney
well
spleen
liver
intraven
inject
find
may
explain
intraven
administr
mscderiv
exosom
stimul
recoveri
cisplatininduc
acut
kidney
injuri
scid
mice
see
studi
vivo
behavior
dirlabel
exosom
variou
cell
type
murin
melanoma
cell
murin
myoblast
cell
bone
marrowderiv
dc
human
embryon
kidney
cell
exosom
mainli
distribut
liver
spleen
lung
gastrointestin
tract
intraven
administr
among
exosom
murin
melanoma
cellderiv
exosom
mainli
accumul
lung
compar
exosom
deriv
two
type
murin
cell
highest
accumul
spleen
liver
observ
dc
exosom
exosom
respect
exosom
mainli
accumul
liver
intraven
inject
liver
pancrea
gastrointestin
tract
intraperiton
subcutan
inject
respect
see
higher
sensit
stabil
label
exosom
radiotrac
appropri
method
quantit
assess
pharmacokinet
tissu
distribut
exosom
compar
label
fluoresc
dye
chemiluminesc
protein
exampl
inlabel
exosom
rapidli
disappear
blood
circul
primarili
distribut
liver
inject
dose
id
g
h
intraven
inject
see
variou
type
cell
recogn
take
exosom
therefor
identifi
cell
import
explor
biolog
exosom
develop
exosomebas
therapeut
mous
dcderiv
exosom
pick
macrophag
spleen
liver
see
exosom
deriv
breast
cancer
cell
taken
macrophag
lung
brain
intraven
administr
respect
exosom
deriv
cell
cell
maec
cell
cell
mainli
pick
macrophag
liver
intraven
administr
see
result
suggest
macrophag
main
cell
activ
take
exogen
exosom
see
predict
exosom
taken
cell
recognit
surfac
molecul
membran
exosom
sever
studi
investig
molecul
may
contribut
vivo
pharmacokinet
exosom
vitro
studi
prove
carbohydr
moieti
membran
exosom
contribut
cellular
uptak
exosom
see
exosom
deriv
tumor
cell
metastas
lung
liver
hpafii
mainli
gather
lung
liver
respect
proteom
analysi
exosom
show
high
express
integrin
respect
exosom
collect
integrin
cell
show
reduc
accumul
lung
result
demonstr
integrin
play
key
role
pharmacokinet
tissu
distribut
exosom
vivo
see
exosom
deriv
genet
modifi
immatur
dc
express
irgd
peptid
show
select
distribut
integrinposit
tumor
tissu
see
addit
deliveri
small
rna
molecul
depend
intracellular
deliveri
perform
intrins
function
ev
also
appli
deliv
chemotherapeut
agent
aim
increas
efficaci
reduc
advers
effect
one
studi
involv
use
exosom
deliv
curcumin
treat
inflammatori
diseas
see
exosom
appli
form
complex
curcumin
enhanc
curcumin
anticanc
activ
see
intraven
inject
integrintarget
dendrit
cellderiv
ev
chemotherapeut
doxorubicin
led
signific
repress
tumor
growth
compar
free
doxorubicin
mous
model
breast
tumor
moreov
doxorubicin
load
ev
shown
caus
less
cardiac
damag
otherwis
import
doselimit
advers
effect
see
advantag
exosom
doxorubicin
versu
liposom
doxorubicin
involv
natur
orient
exosom
membran
protein
abil
interact
receptor
target
cell
plasma
membran
see
furthermor
exosomeencapsul
paclitaxel
compar
free
taxol
shown
effect
control
growth
lewi
lung
carcinoma
metastas
hold
signific
potenti
deliveri
variou
chemotherapeut
treat
drugresist
cancer
see
repeat
intraperiton
inject
cisplatinload
ev
improv
longterm
surviv
ovarian
cancerbear
mice
compar
free
cisplatin
intraven
inject
doxorubicinload
ev
delay
growth
establish
subcutan
hepat
cancer
see
importantli
exosomeencapsul
drug
advers
affect
liver
kidney
function
frequent
observ
administr
free
drug
regrett
movement
larg
protein
bloodbrain
barrier
bbb
sever
limit
fact
potent
drug
may
better
option
variou
cn
diseas
appli
clinic
cross
bbb
see
variou
nanos
drug
formul
develop
overcom
hurdl
see
parkinson
diseas
pd
known
associ
brain
inflamm
microglia
activ
secretori
neurotox
activ
includ
reactiv
oxygen
speci
ro
see
sampl
brain
tissu
patient
pd
shown
reduc
level
redox
enzym
catalas
superoxid
dismutas
antioxid
see
indic
impair
defens
oxid
stress
neurodegener
patient
among
molecul
catalas
one
effect
natur
antioxid
scaveng
one
million
free
radic
catalyt
reaction
therefor
success
deliveri
catalas
brain
may
import
possibl
approach
pd
therapi
see
ev
propos
therapeut
deliveri
vehicl
treatment
pd
exosom
readili
taken
neuron
cell
vitro
consider
number
exosom
detect
pd
mous
brain
intranas
administr
catalaseload
exosom
exocat
shown
suppress
microgli
activ
protect
neuron
ro
effici
compar
free
catalas
vitro
vivo
model
pd
see
therefor
exocat
adapt
strategi
treat
inflammatori
degen
disord
pd
see
although
report
preliminari
result
shown
exosom
promis
candid
drug
deliveri
system
treatment
varieti
diseas
exosom
deriv
human
adipos
tissuederiv
mesenchym
stem
cell
msc
consid
therapeut
valu
treat
ad
see
exosom
use
vivo
vehicl
carri
activ
neprilysin
nep
import
enzym
peptid
degrad
brain
mscderiv
exosom
also
decreas
intracellular
extracellular
level
neuroblastoma
cell
line
vitro
therefor
human
adipos
tissuederiv
mscorigin
exosom
propos
potenti
therapi
ad
point
view
capac
recent
studi
demonstr
multipot
mesenchym
stromal
cell
msc
hold
great
promis
neurovascular
remodel
neurolog
function
recoveri
follow
stroke
demonstr
mscderiv
exosom
neuroprotect
effect
stroke
due
part
chang
mirna
profil
exosom
stroke
see
consid
problem
associ
mani
current
nanoparticul
deliveri
system
exosom
mimic
natur
deliveri
system
potenti
altern
deliveri
biolog
molecul
describ
small
size
hostderiv
cellular
product
vesicl
avoid
phagocytosi
degrad
macrophag
also
circul
long
period
time
bodi
one
interest
advantag
deliveri
vehicl
includ
abil
cross
bbb
arriv
cn
see
insuffici
knowledg
natur
exosom
role
pathophysiolog
overal
health
diseas
make
complic
difficult
predict
longterm
safeti
therapeut
effect
vivo
traffick
exosom
biolog
fate
impact
target
organ
need
understood
regard
therapeut
cargo
load
assembl
drug
deliveri
see
current
distinct
optim
purif
techniqu
isol
exosom
high
puriti
see
current
isol
method
yield
low
quantiti
exosom
largescal
product
clinic
studi
post
drug
approv
expens
complic
see
highli
like
futur
clinic
use
demand
hybrid
design
exosom
see
combin
therapeut
cargo
may
show
undesir
effect
even
though
extens
exosom
biolog
alreadi
known
exosom
compris
heterogen
constitu
may
show
immunogen
stimulatori
suppress
effect
base
natur
donor
cell
exosom
provid
immens
promis
new
therapeut
area
deliveri
variou
synthet
biolog
molecul
cellular
therapi
exosom
drug
deliveri
system
provid
major
advantag
undesir
aggreg
home
exosom
liver
andor
firstpass
effect
arriv
target
site
wellcharacter
exosom
longterm
safeti
deliv
nucleic
acid
therapeut
molecul
cell
difficulttocross
membran
bbb
would
major
practic
signific
howev
drug
deliveri
system
becom
therapeut
realiti
compon
process
includ
immun
reaction
need
clarifi
see
emerg
evid
tumor
cellderiv
exosom
uniqu
properti
may
use
develop
exosomebas
drug
deliveri
system
better
synthet
drug
carrier
howev
limit
hurdl
must
overcom
exosomebas
drug
deliveri
system
use
clinic
import
issu
still
need
autolog
nonimmunogen
exosom
factori
therefor
strategi
need
develop
manufactur
vesicl
therapeut
applic
establish
produc
cell
type
physic
method
produc
vesicular
nanoparticl
enhanc
ev
yield
scaleup
measur
potenc
evbas
product
evinspir
bioengin
artifici
vesicl
recent
group
research
develop
method
produc
exosomemimet
vesicl
overcom
natur
exosom
limit
like
low
drugload
effici
low
exosom
product
yield
see
chemotherapeuticload
nanovesicl
nm
diamet
gener
break
cell
serial
extrus
filter
diminish
pore
size
see
suggest
nanovesicl
exosomemimet
properti
use
platform
rnai
transfer
cell
cytoplasm
see
howev
high
level
cholesterol
gangliosid
sphingomyelin
exosom
membran
lead
rigid
bilay
structur
parent
cell
see
suggest
fusion
lipidbas
particl
requir
rough
condit
see
aggress
freezethaw
process
see
avoid
need
condit
yang
et
al
design
virusmimet
fusogen
exosom
platform
deliv
membran
protein
target
cell
membran
involv
integr
vascular
stomat
viru
g
protein
viral
fusogen
see
interestingli
method
allow
easi
exosom
modif
fuse
exosom
deriv
modifi
cell
liposom
insert
peptid
antibodi
polyethylen
glycol
although
current
mani
challeng
treatment
cancer
refractori
diseas
exosom
includ
exosomemimet
nanovesicl
consid
valid
diagnost
biomark
potenti
therapeut
tool
moreov
along
chemic
physic
cellular
genet
engin
techniqu
mani
exist
exosom
modif
strategi
promis
applic
variou
clinic
situat
fig
